Treatment of anemia with methoxypolyethyleneglycol - epoetin beta in patients on haemodyalisis


如何引用文章

全文:

详细

Aim. Determination of efficacy and safety of methoxypolyethyleneglycol-epoetin beta (MEB) in patients with terminal renal failure on hemodyalysis, who previously received recombinant human erythropoietin (rhEPO) preparations.
Methods. 30 patients (14 male, 16 female, mean age 58,5±14,6 years) with terminal renal failure on hemodyalysis were included into prospective study. Baseline hemoglobin (Hb) level was 100 - 130 g/l. All patients were switched from rhEPO to MEB. Duration of study was 12 months.
Results. Mean Hb level at the end of the study was 115,5±13,2 g/l; mean haematocrit level - (Hct) - 33,4±3,2%; no significant difference from baseline levels was detected. Target Hb level was maintained with MEB in 12 months in 85%. Blood pressure levels were stable. MEB was well tolerated.
Conclusion. MEB is effective in maintenance of Hb level in patient on hemodialysis, previously treated with rhEPO

参考

  1. Библиография
  2. Земченков А.Ю., Герасимчук Р.П., Костылева Т.Г. и др. Оценка эффективности и безопасности нового отечественного препарата - эритропоэтина альфа. // Нефрология и диализ, 2010. Т.12, №4, С.289-296.
  3. Adamson JW. Iron deficiency and other hypoproliferative anemias. // In: Harrison's Principles of Internal Medicine / Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL, 16th ed. New York, NY: McGraw-Hill. 2005. P. 586-592.
  4. Cain SM. Oxygen delivery and uptake in dogs during anemic and hypoxic hypoxia. J Appl Physiol 1977; 42:228-234.
  5. Canaud B, Mingardi G, Braun J, et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study // Nephrol Dial Transplant. 2008.Vol. 23(11). P. 3654-3661.
  6. Carrera F, Lok CE, de Francisco A. et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxypolyethyleneglycol - epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. // Nephrol Dial Transplant. 2010. Vol. 25(12). P. 4009-4017.
  7. Drueke TB, Locatelli F, Clyne N. et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. // N Engl J Med. 2006. Vol. 355. P. 2071-2084.
  8. Ebben JP, Gilbertson DT, Foley RN et al. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. // Clin J Am Soc Nephrol. 2006; Vol.1, P. 1205-1210.
  9. Eckardt KU, Kim J, Kronenberg F. et al. Hemoglobin variability does not predict mortality in European hemodialysis patients. // Am Soc Nephrol. 2010. Vol. 21(10). P.1765-1775.
  10. Fishbane S. Recombinant human erythropoietin: has treatment reached its full potential? // Semin Dial. 2006. Vol. 19. P.1-4.
  11. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. // Kidney Int 2005. Vol.68. P.1337-1343.
  12. Jarsch M, Brandt M, Lanzendörfer M, Haselbeck A. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. // Pharmacology. 2008. Vol. 81. P.63-69.
  13. Klinger M., Arias M., Vargemezis V. et al. Efficacy of intravenous methoxypolyethyleneglycol-epoietin beta administered every 2 weeks compared with epoietin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. // Am. J. Kidney Dis. 2007. Vol. 50. P. 989-1000.
  14. Lau JH, Gangji AS, Rabbat CG, Brimble KS. Impact of haemoglobin and erythropoietin dose changes on mortality: a secondary analysis of results from a randomized anaemia management trial. // Nephrol Dial Transplant. 2010. Vol. 25(12) P.4002-4009.
  15. Levin NW, Fishbane S, Valdés Cañedo F. et al. On behalf of the MAXIMA study investigators. Intravenous methoxypolyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomized non-inferiority trial (MAXIMA). // Lancet. 2007. Vol. 370. P. 1415-1421.
  16. Li S, C Besarab A, Bolton WK. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. // N Engl J Med. 1998. Vol.339. P. 584 -590.
  17. Locatelli F., Mann J., Aldigier J. et al. C.E.R.A. safety profile a pooled analysis in patients with chronic kidney disease. // Clinical Nephrology. 2010. Vol. 73. P. 94-103.
  18. Macdougall IC, Eckardt KU. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. // Lancet. 2006. Vol. 368. P. 947-953.
  19. Macdougall IC, Robson R., Opatrna S. et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. //.Clin J Am Soc Nephrol. 2006. Vol. 1. P. 1211-1215.
  20. Macdougall IC. CERA (Continuous Erythropoietin Receptor Activator): A new erythropoiesisstimulating agent for the treatment of anemia. // Curr Hematol Rep. 2005.Vol. 4.P. 436-440.
  21. Manley H., Debra R., Drayer R., et al. Medication-related problem type and appearance rate in ambulatory hemodialysis patients. // BMC Nephrol. 2003. Vol. 4. P. 4-10.
  22. Manley H., Cannela C., Bailie C., St. Peter W. Medication-related problem in ambulatory hemodialysis patients a pooled analysis. // Am J Kidney Dis 2005. Vol.46(4) P. 669-680.
  23. McClellan W., Jurkovitz C., Abramson J. The epidemiology and control of anemia among pre-ESRD patients with chronic kidney disease. // Eur. J. Clin Investig. 2005. Vol. 35, Suppl. 3. P. 58-65
  24. Pisoni RL, Bragg-Gresham JL, Fuller DS et al. Facility-level interpatient hemoglobin variability in hemodialysis centers participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS): Associations with mortality, patient characteristics, and facility practices. // Am J Kidney Dis. 2011. Vol. 57(2), P. 266-275.
  25. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. // N Engl J Med. 2006. Vol. 355. P. 2085-2098.
  26. Spinowitz B, Coyne DW, Lok CE. RUBRA Study Investigators. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. // Am J Nephrol. 2008. Vol. 28. P. 280-289.
  27. Sulowicz W., Locatelli F., Ryckenlynck J-P. et al. On behalf of the PROTOS Study Investigators. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic Kidney disease on dialysis converted directly from epoetin one to three times weekly. // Clin. J. Am. Soc. Nephrol. 2007. Vol. 2. P. 637-646.
  28. Weinhandl ED, Peng Y, Gilbertson DT et al. Hemoglobin variability and mortality: confounding by disease severity. // Am J Kidney Dis. 2011. Vol. 57(2). P. 255-265.
  29. Yang W, Israni RK, Brunelli SM et al. Hemoglobin variability and mortality in ESRD. // J Am Soc Nephrol. 2007. Vol. 18. P. 3164-3170.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##